Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells

Cellular Immunology

Volumn 208, Issue 2, 2001, Pages 107-114

  Xu, Likang ^a   Villain, Matteo ^a   Galin, F Shawn ^a   Araga, Shigeru ^b   Blalock, J Edwin ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Antigen peptides epitopes; Autoimmunity; Neuroimmunology; T cell receptors; Th1 Th2

Indexed keywords

CHOLINERGIC RECEPTOR; GAMMA INTERFERON; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL DIVISION; FEMALE; IMMUNOLOGY; LEWIS RAT; MYASTHENIA GRAVIS; RAT; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL DIVISION; FEMALE; INTERFERON TYPE II; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES;

EID: 0035002763     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1006/cimm.2001.1777     Document Type: Article

References (50)

1. Drachman, D. B., The biology of myasthenia gravis. Annu. Rev. Neurosci. 4, 195-225, 1981.
2. Johns, T. R., Long-term corticosteroid treatment of myasthenia gravis. Ann. N. Y. Acad. Sci. 505, 568-583, 1987.
3. Matell, G., Immunosuppressive drugs: Azathioprine in the treatment of myasthenia gravis. Ann. N. Y. Acad. Sci. 505, 589-594, 1987.
4. Araga, S., Xu, L., Nakashima, K., Villain, M., and Blalock, J. E., A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help. FASEB J. 14, 185-196, 2000.
5. Blalock, J. E., Genetic origins of protein shape and interaction rules. Nat. Med. 1, 876-878, 1995.
6. Villain, M., Jackson, P. L., Manion, M. K., Dong, W. J., Su, Z., Fassina, G., Johnson, T. M., Sakai, T. T., Krishna, N. R., and Blalock, J. E., De novo design of peptides targeted to the EF hands of calmodulin. J. Biol. Chem. 275, 2676-2685, 2000.
7. Baranyi, L., Campbell, W., Ohshima, K., Fujimoto, S., Boros, M., and Okada, H., The antisense homology box: A new motif within proteins that encodes biologically active peptides. Nat. Med. 1, 894-901, 1995.
8. Crawford, S. E., Stellmach, V., Murphy-Ullrich, J. E., Ribeiro, S. M., Lawler, J., Hynes, R. O., Boivin, G. P., and Bouck, N., Thrombospondin-1 is a major activator of TGF-betal in vivo. Cell 93, 1159-1170, 1998.
9. Ribeiro, S. M., Poczatek, M., Schultz-Cherry, S., Villain, M., and Murphy-Ullrich, J. E., The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J. Biol. Chem. 274, 13586-13593, 1999.
10. Ghiso, J., Saball, E., Leoni, J., Rostagno, A., and Frangione, B., Binding of cystatin C to C4: The importance of sense-antisense peptides in their interaction. Proc. Natl. Acad. Sci. USA 87, 1288-1291, 1990.
11. Palla, E., Bensi, G., Solito, E., Buonamassa, D. T., Fassina, G., Raugei, G., Spano, F., Galeotti, C., Mora, M., and Domenighini, M., Loop substitution as a tool to identify active sites of interleukin-1 beta. J. Biol. Chem. 268, 13486-13492, 1993.
12. Ruiz-Opazo, N., Akimoto, K., and Herrera, V. L., Identification of a novel dual angiotensin II/vasopressin receptor on the basis of molecular recognition theory. Nat. Med. 1, 1074-1081, 1995.
13. Smith, L. R., Bost, K. L., and Blalock, J. E., Generation of idiotypic and anti-idiotypic antibodies by immunization with peptides encoded by complementary RNA: A possible molecular basis for the network theory. J. Immunol. 138, 7-9, 1987.
14. Whitaker, J. N., Sparks, B. E., Walker, D. P., Goodin, R., and Benveniste, E. N., Monoclonal idiotypic and anti-idiotypic antibodies produced by immunization with peptides specified by a region of human myelin basic protein mRNA and its complement. J. Neuroimmunol. 22, 157-166, 1989.
15. Zhou, S. R., Han, Q., LaGanke, C. C., and Whitaker, J. N., Comparison of properties of murine monoclonal anti-idiotypic antibodies generated with idiotype-bearing monoclonal antibodies to myelin basic protein peptides or their complementary peptides. Clin. Immunol. Immunopathol. 70, 251-259, 1994.
16. Zhou, S. R., and Whitaker, J. N., Use of complementary peptides and their antibodies in T-cell-mediated autoimmune disease: Experiments with myelin basic protein. Immunomethods 5, 136-147, 1994.
17. Zhou, S. R., and Whitaker, J. N., Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. J. Immunol. 150, 1629-1642, 1993.
18. Zhou, S. R., Whitaker, J. N., Han, Q., Maier, C., and Blalock, J. E., A cross-reactive idiotope on T cells from PL/J mice and Lewis rats that recognizes different myelin basic protein encephalitogenic epitopes but is restricted by TCR V beta 8.2. J. Immunol. 153, 2340-2351, 1994.
19. Araga, S., LeBoeuf, R. D., and Blalock, J. E., Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Proc. Natl. Acad. Sci. USA 90, 8747-8751, 1993.
20. Araga, S., Galin, F. S., Kishimoto, M., Adachi, A., and Blalock, J. B., Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. J. Immunol. 157, 386-392, 1996.
21. Boquet, D., Dery, O., Frobert, Y., Grassi, J., and Couraud, J. Y., Is hydropathic complementarity involved in antigen-antibody binding? Mol. Immunol. 32, 303-308, 1995.
22. Blalock, J. E., Whitaker, J. N., Benveniste, E. N., and Bost, K. L., Use of peptides encoded by complementary RNA for generating anti-idiotypic antibodies of predefined specificity. Methods Enzymol. 178, 63-74, 1989.
23. Bost, K. L., Smith, E. M., and Blalock, J. E., Similarity between the corticotropin (ACTH) receptor and a peptide encoded by an RNA that is complementary to ACTH mRNA. Proc. Natl. Acad. Sci. USA 82, 1372-1375, 1985.
24. Dery, O., Frobert, Y., Zerari, F., Creminon, C., Grassi, J., Fischer, J., Conrath, M., and Couraud, J. Y., A monoclonal antibody to the ligand-binding domain of the neurokinin 1 receptor (NK1-R) for the neuropeptide substance P. J. Neuroimmunol. 76, 1-9, 1997.
25. Martins, V. R., Graner, E., Garcia-Abreu, J., de Souza, S. J., Mercadante, A. F., Veiga, S. S., Zanata, S. M., Neto, V. M., and Brentani, R. R., Complementary hydropathy identifies a cellular prion protein receptor. Nat. Med. 3, 1376-1382, 1997.
26. McGuigan, J. E., Antibodies to complementary peptides as probes for receptors. Immunomethods 5, 158-166, 1994.
27. Blalock, J. E., Complementarity of peptides specified by "sense" and "antisense" strands of DNA. Trends Biotechnol. 8, 140-144, 1990.
28. Borovsky, D., Powell, C. A., Nayar, J. K., Blalock, J. E., and Hayes, T. K., Characterization and localization of mosquito-gut receptors for trypsin modulating oostatic factor using a complementary peptide and immunocytochemistry. FASEB J. 8, 350-355, 1994.
29. Pascual, D. W., and Bost, K. L., Anti-peptide antibodies recognize anti-substance P antibodies in an idiotypic fashion. Pept. Res. 2, 207-212, 1989.
30. Kaul, R., Shenoy, M., Goluszko, E., and Christadoss, P., Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152, 3152-3157, 1994.
31. Christadoss, P., and Dauphinee, M. J., Immunotherapy for myasthenia gravis: A murine model. J. Immunol. 136, 2437-2440, 1986.
32. Waldor, M. K., Sriram, S., McDevitt, H. O., and Steinman, L., In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc. Natl. Acad. Sci. USA 80, 2713-2717, 1983.
33. + T cells are essential to induce experimental autoimmune myasthenia gravis. J. Exp. Med. 184, 349-356, 1996.
34. Moiola, L., Galbiati, F., Martino, G., Amadio, S., Brambilla, E., Comi, G., Vincent, A., Grimaldi, L. M., and Adorini, L., IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28, 2487-2497, 1998.
35. Balasa, B., Deng, C., Lee, J., Bradley, L. M., Dalton, D. K., Christadoss, P., and Sarvetnick, N., Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptorinduced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186, 385-391, 1997.
36. Froehner, S. C., and Rafto, S., Comparison of the subunits of Torpedo californica acetylcholine receptor by peptide mapping. Biochemistry 18, 301-307, 1979.
37. Barchan, D., Souroujon, M. C., Im, S. H., Antozzi, C., and Fuchs, S., Antigen-specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit. Proc. Natl. Acad. Sci. USA 96, 8086-8091, 1999.
38. Mosmann, T. R., and Sad, S., The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17, 138-146, 1996.
39. Fernandez-Botran, R., Sanders, V. M., Mosmann, T. R., and Vitetta, E. S., Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J. Exp. Med. 168, 543-558, 1988.
40. Gajewski, T. F., and Fitch, F. W., Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol. 140, 4245-4252, 1988.
41. Powrie, F., Menon, S., and Coffman, R. L., Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 23, 2223-2229, 1993.
42. Powrie, F., and Coffman, R. L., Cytokine regulation of T-cell function: Potential for therapeutic intervention. Immunol. Today 14, 270-274, 1993.
43. Zhang, G. X., Xiao, B. G., Bai, X. F., van der Meide, P. H., Orn, A., and Link, H., Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162, 3775-3781, 1999.
44. Sidman, C. L., Marshall, J. D., Shultz, L. D., Gray, P. W., and Johnson, H. M., Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature 309, 801-804, 1984.
45. Snapper, C. M., and Mond, J. J., Towards a comprehensive view of immunoglobulin class switching. Immunol. Today 14, 15-17, 1993.
46. Rizzo, L. V., DeKruyff, R. H., and Umetsu, D. T., Generation of B cell memory and affinity maturation: Induction with Th1 and Th2 T cell clones. J. Immunol. 148, 3733-3739, 1992.
47. Drachman, D. B., McIntosh, K. R., and Yang, B., Factors that determine the severity of experimental myasthenia gravis. Ann. N. Y. Acad. Sci. 841, 262-282, 1998.
48. Balasa, B., Deng, C., Lee, J., Christadoss, P., and Sarvetnick, N., The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J. Immunol. 161, 2856-2862, 1998.
49. Graus, Y. M., van, B., V, and de Baets, M. H., Characterization of anti-acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis (EAMG). Clin. Exp. Immunol. 92, 506-513, 1993.
50. Krolick, K. A., Zoda, T. E., and Thompson, P. A., Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis. Adv. Neuroimmunol. 4, 475-493, 1994.